# A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

> **NCT05377580** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 150 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Period 1 IBI112 Placebo
- **DRUG:** Period 2 IBI112 dose 3
- **DRUG:** Period 1 IBI112 dose 1
- **DRUG:** Period 1 IBI112 dose 2
- **DRUG:** Period 2 IBI112 dose 4
- **DRUG:** Period 2 IBI112 Placebo

## Key facts

- **NCT ID:** NCT05377580
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2024-06-21
- **Final completion:** 2025-08-07
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377580, "A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05377580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*